Stoke Therapeutics (STOK) Competitors $19.77 +0.18 (+0.92%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$19.72 -0.05 (-0.25%) As of 09/3/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock STOK vs. ADMA, TLX, PCVX, PTCT, LNTH, ACLX, AKRO, ZLAB, MIRM, and MLTXShould you be buying Stoke Therapeutics stock or one of its competitors? The main competitors of Stoke Therapeutics include ADMA Biologics (ADMA), Telix Pharmaceuticals (TLX), Vaxcyte (PCVX), PTC Therapeutics (PTCT), Lantheus (LNTH), Arcellx (ACLX), Akero Therapeutics (AKRO), Zai Lab (ZLAB), Mirum Pharmaceuticals (MIRM), and MoonLake Immunotherapeutics (MLTX). These companies are all part of the "pharmaceutical products" industry. Stoke Therapeutics vs. Its Competitors ADMA Biologics Telix Pharmaceuticals Vaxcyte PTC Therapeutics Lantheus Arcellx Akero Therapeutics Zai Lab Mirum Pharmaceuticals MoonLake Immunotherapeutics ADMA Biologics (NASDAQ:ADMA) and Stoke Therapeutics (NASDAQ:STOK) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, media sentiment, risk, profitability, dividends and analyst recommendations. Do institutionals & insiders have more ownership in ADMA or STOK? 75.7% of ADMA Biologics shares are owned by institutional investors. 3.7% of ADMA Biologics shares are owned by insiders. Comparatively, 9.5% of Stoke Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Do analysts recommend ADMA or STOK? ADMA Biologics currently has a consensus target price of $27.67, suggesting a potential upside of 63.71%. Stoke Therapeutics has a consensus target price of $25.57, suggesting a potential upside of 29.34%. Given ADMA Biologics' stronger consensus rating and higher possible upside, analysts clearly believe ADMA Biologics is more favorable than Stoke Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ADMA Biologics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33Stoke Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.22 Is ADMA or STOK more profitable? ADMA Biologics has a net margin of 44.06% compared to Stoke Therapeutics' net margin of 26.25%. ADMA Biologics' return on equity of 41.01% beat Stoke Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets ADMA Biologics44.06% 41.01% 28.47% Stoke Therapeutics 26.25%18.32%15.48% Which has better earnings & valuation, ADMA or STOK? ADMA Biologics has higher revenue and earnings than Stoke Therapeutics. ADMA Biologics is trading at a lower price-to-earnings ratio than Stoke Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioADMA Biologics$426.45M9.46$197.67M$0.8619.65Stoke Therapeutics$36.56M29.63-$88.98M$0.8523.26 Does the media refer more to ADMA or STOK? In the previous week, Stoke Therapeutics had 5 more articles in the media than ADMA Biologics. MarketBeat recorded 14 mentions for Stoke Therapeutics and 9 mentions for ADMA Biologics. ADMA Biologics' average media sentiment score of 1.62 beat Stoke Therapeutics' score of 0.66 indicating that ADMA Biologics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADMA Biologics 9 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Stoke Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, ADMA or STOK? ADMA Biologics has a beta of 0.54, indicating that its share price is 46% less volatile than the S&P 500. Comparatively, Stoke Therapeutics has a beta of 1.14, indicating that its share price is 14% more volatile than the S&P 500. SummaryADMA Biologics beats Stoke Therapeutics on 10 of the 17 factors compared between the two stocks. Get Stoke Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for STOK and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding STOK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart STOK vs. The Competition Export to ExcelMetricStoke TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.08B$3.11B$5.77B$9.76BDividend YieldN/A2.28%6.66%4.49%P/E Ratio23.2621.1082.3726.60Price / Sales29.63371.03525.77170.66Price / CashN/A43.5325.7028.92Price / Book3.248.1310.646.56Net Income-$88.98M-$53.35M$3.28B$266.04M7 Day PerformanceN/A0.73%0.09%-0.89%1 Month Performance50.46%7.76%8.90%4.34%1 Year Performance27.63%11.97%48.37%24.06% Stoke Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)STOKStoke Therapeutics4.6074 of 5 stars$19.77+0.9%$25.57+29.3%+31.5%$1.08B$36.56M23.26100News CoverageInsider TradeGap DownADMAADMA Biologics3.9279 of 5 stars$17.01-4.4%$27.67+62.6%+2.0%$4.25B$426.45M19.78530Positive NewsTLXTelix PharmaceuticalsN/A$12.20-2.2%$22.33+83.1%N/A$4.22B$516.72M0.00N/AAnalyst RevisionGap DownPCVXVaxcyte2.7844 of 5 stars$30.45-5.7%$136.50+348.3%-70.9%$4.19BN/A-7.41160News CoveragePositive NewsPTCTPTC Therapeutics3.8467 of 5 stars$49.30-2.5%$69.15+40.3%+66.3%$4.02B$806.78M7.071,410News CoverageAnalyst ForecastLNTHLantheus4.8872 of 5 stars$56.16-3.5%$105.50+87.9%-47.7%$3.96B$1.53B14.94700Positive NewsShort Interest ↓ACLXArcellx2.1804 of 5 stars$68.49-3.9%$114.31+66.9%+7.7%$3.95B$107.94M-20.0380News CoveragePositive NewsAKROAkero Therapeutics3.9051 of 5 stars$47.03-4.5%$81.57+73.4%+75.5%$3.94BN/A-23.5230News CoveragePositive NewsZLABZai Lab2.5321 of 5 stars$34.03-2.9%$56.35+65.6%+61.8%$3.92B$398.99M-16.681,869News CoverageMIRMMirum Pharmaceuticals3.4401 of 5 stars$71.81+0.4%$74.13+3.2%+80.6%$3.59B$336.89M-59.35140Positive NewsMLTXMoonLake Immunotherapeutics2.2385 of 5 stars$54.63-2.3%$74.43+36.2%+28.5%$3.59BN/A-19.652Positive News Related Companies and Tools Related Companies ADMA Alternatives TLX Alternatives PCVX Alternatives PTCT Alternatives LNTH Alternatives ACLX Alternatives AKRO Alternatives ZLAB Alternatives MIRM Alternatives MLTX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:STOK) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredFree: The Crypto Summit That Could Change Your Life27 industry leaders share urgent market intel (free access)... For a very limited time, you can claim your ...Crypto 101 Media | SponsoredThis Massive Market is Ripe for Disruption by this NasdaqFanatics Hit $31B. This Nasdaq Company Is Building the Next Wave Fanatics built a merch empire by owning th...i2i Marketing Group, LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Stoke Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Stoke Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free STOK Stock Alerts